Abstract Body

Background

Broadly neutralizing antibodies (bNAbs) hold promise for HIV perinatal prophylaxis. Three anti-CD4 binding site bNAbs, VRC01, VRC01LS (longer plasma half-life), and VRC07-523LS (greater potency, longer plasma half-life), have favorable plasma pharmacokinetics (PK) when administered subcutaneously (SC) to newborns exposed to HIV. Concentrations of bNAbs in oral secretions (OS) may be relevant to protection from HIV mucosal transmission in breastfeeding infants.

Methods

Study sites in the US, S. Africa, and Zimbabwe administered VRC01, VRC01LS, or VRC07-523LS SC to newborns at increased risk of HIV. Dose groups (DGs), non-randomized and sequentially enrolled, received a birth dose (<5 days of age) of VRC01 20 mg/kg (DG1), VRC01 40 mg/kg (DG2), VRC01LS 80 mg fixed dose (DG3; mean 28 mg/kg), or VRC07-523LS 80 mg fixed dose (DG4; mean 28 mg/kg). All infants and mothers also received local standard-of-care antiretroviral therapy. Concentrations of bNAb in OS were tested in duplicate by binding antibody multiplex assay using 5-PL logistic regression from individual monoclonal Ab-specific standard curves on the same plate with lower limit of quantitation (LLOQ) of 1 ng/mL. OS concentrations were determined on Days 0, 1, 3, 28, and 56 (all DG); Day 7 (DG1, 2, 4); Day 14 (DG3); Wk 12 (DG4); Wk 16 (DG1, 2); Wk 24 (DG3).

Results

64 infants had evaluable OS (n=13, 11, 19, 21, in DG1-4, respectively). No infants had bNAb detected at entry. At Day 1 after the birth dose, OS had detectable bNAbs in 62%, 82%, 68%, and 48% of infants in DG1-4, respectively. In the frequently tested DG1 & 2, Tmax was Day 3. Geometric mean (10th, 90th percentile) concentrations on Day 7 (Day 14 for DG3) were 34.5 (<1, 160), 106 (<1, 170), 112 (40, 410) and 15.4 (<1, 90) ng/mL for DG1-4, respectively. OS concentrations were approximately 3 log mg/mL lower than plasma (previously reported) for all DG. Clearance of VRC01LS was slowest, with quantifiable VRC01LS persisting in 13/17 (76%) at Week 12 in DG3. By contrast, VRC07-523L OS clearance was faster than VRC01LS and VRC01 (Figure).

Conclusions

VRC01, VRC01LS, VRC07-523LS were frequently detected in OS by Day 1 post-SC administration to newborns. Clearance of VRC01LS from OS was slower than VRC01, consistent with its longer plasma half-life. However, clearance of VRC07-523LS from OS was more rapid than VRC01 despite its longer plasma half-life. Further studies are needed to elucidate the mechanism and implications of differential bNAb PK in OS.

Table or Figure